Search research articles
Contact Us
Filters
Showing results (281-290 of 418) with videos related to
Page
of 42
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
June 5, 2023
Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study
Alessandro Rossi, Giacomo Aimar, Marco Audisio, et al.
The Oncologist
|
March 24, 2020
The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer
Debora Basile, Silvio Ken Garattini, Carla Corvaja, et al.
Oncotarget
|
September 17, 2017
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib <i>versus</i> chemotherapy in advanced non-small cell lung cancer patients
Lucia Kim, Mauro Saieg, Massimo Di Maio, et al.
British Journal of Cancer
|
March 18, 2025
Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status
Sandro Pignata, Amit Oza, Geoff Hall, et al.
Pediatric Nephrology (Berlin, Germany)
|
February 26, 2021
Safety, efficacy, and acceptability of ADV7103 during 24 months of treatment: an open-label study in pediatric and adult patients with distal renal tubular acidosis
Aurélia Bertholet-Thomas, Catherine Guittet, Maria A Manso-Silván, et al.
Eclinicalmedicine
|
October 25, 2023
Position paper of the Italian association of medical oncology on health disparities among transgender and gender-diverse people: the Assisi recommendations
Alberto Giovanni Leone, Raffaella Casolino, Dario Trapani, et al.
Frontiers in Oncology
|
February 6, 2024
Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors
Francesca Arezzo, Gaia Giannone, Daniele Castaldo, et al.
Pediatric Nephrology (Berlin, Germany)
|
September 29, 2020
Correction to: Efficacy and safety of an innovative prolonged-release combination drug in patients with distal renal tubular acidosis: an open-label comparative trial versus standard of care treatments
Aurélia Bertholet-Thomas, Catherine Guittet, Maria A Manso-Silván, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2010
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study
Giuseppe Colucci, Roberto Labianca, Francesco Di Costanzo, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 20, 2017
A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial
Alessandro Morabito, Gennaro Daniele, Raffaele Costanzo, et al.
Page
of 42
Search research articles
Search
Showing results (281-290 of 418) with videos related to
Sort By:
Page
of 42
European Journal of Cancer (Oxford, England : 1990)
|
June 5, 2023
Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study
Alessandro Rossi, Giacomo Aimar, Marco Audisio, et al.
The Oncologist
|
March 24, 2020
The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer
Debora Basile, Silvio Ken Garattini, Carla Corvaja, et al.
Oncotarget
|
September 17, 2017
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib <i>versus</i> chemotherapy in advanced non-small cell lung cancer patients
Lucia Kim, Mauro Saieg, Massimo Di Maio, et al.
British Journal of Cancer
|
March 18, 2025
Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status
Sandro Pignata, Amit Oza, Geoff Hall, et al.
Pediatric Nephrology (Berlin, Germany)
|
February 26, 2021
Safety, efficacy, and acceptability of ADV7103 during 24 months of treatment: an open-label study in pediatric and adult patients with distal renal tubular acidosis
Aurélia Bertholet-Thomas, Catherine Guittet, Maria A Manso-Silván, et al.
Eclinicalmedicine
|
October 25, 2023
Position paper of the Italian association of medical oncology on health disparities among transgender and gender-diverse people: the Assisi recommendations
Alberto Giovanni Leone, Raffaella Casolino, Dario Trapani, et al.
Frontiers in Oncology
|
February 6, 2024
Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors
Francesca Arezzo, Gaia Giannone, Daniele Castaldo, et al.
Pediatric Nephrology (Berlin, Germany)
|
September 29, 2020
Correction to: Efficacy and safety of an innovative prolonged-release combination drug in patients with distal renal tubular acidosis: an open-label comparative trial versus standard of care treatments
Aurélia Bertholet-Thomas, Catherine Guittet, Maria A Manso-Silván, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2010
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study
Giuseppe Colucci, Roberto Labianca, Francesco Di Costanzo, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 20, 2017
A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial
Alessandro Morabito, Gennaro Daniele, Raffaele Costanzo, et al.
Page
of 42